Radiolabeled mass-balance excretion and metabolism studies in laboratory animals: A commentary on why they are still necessary

Xenobiotica

Volumn 43, Issue 2, 2013, Pages 219-225

  White, Ronald E ^a   Evans, David C ^b   Hop, Cornelis E C A ^c   Moore, David J ^d   Prakash, Chandra ^e   Surapaneni, Sekhar ^f   Tse, Francis L S ^g  

^a XENOBIOTIC LABORATORIES INC   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c GENENTECH INC   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

^e BIOGEN   (United States)

^f CELGENE CORPORATION   (United States)

^g NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

ADME; Biotransformation; Clearance; FDA; Pharmacokinetic; Preclinical; Toxicology; Transporters

Indexed keywords

CYCLOPHOSPHAMIDE; EFAVIRENZ; LASOFOXIFENE; TETRACYCLINE; TORCETRAPIB; VICRIVIROC; ZIPRASIDONE;

DRUG ABSORPTION; DRUG ACTIVITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESEARCH; DRUG SAFETY; EXPERIMENTAL ANIMAL; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; ISOTOPE LABELING; NONHUMAN; RADIOACTIVITY; REVIEW; TOXICOLOGY;

ANIMALS; DRUG EVALUATION, PRECLINICAL; HUMANS; PHARMACEUTICAL PREPARATIONS;

ANIMALIA;

EID: 84872163274     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2012.706724     Document Type: Review

References (21)

1. Chambers HF. (2001) Antimicrobial Agents (Continued) Protein Synthesis Inhibitors and Miscellaneous Antibacterial Agents. In: Hardman JG, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 1239-1271.
2. Christopher LJ, Hong H, Vakkalagadda BJ, Clemens PL, Su H, Roongta V, Allentoff A, Sun H, Heller K, Harbison CT, Iyer RA, Humphreys WG, Wong T, Zhang S. (2010). Metabolism and disposition of [14C] BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans. Drug Metab Dispos 38:2049-2059.
3. Dalvie D, Chen W, Zhang C, Vaz AD, Smolarek TA, Cox LM, Lin J, Obach RS. (2008). Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans. Drug Metab Dispos 36:2185-2198.
4. Ghosal A, Ramanathan R, Yuan Y, Hapangama N, Chowdhury SK, Kishnani NS, Alton KB. (2007). Identification of human liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist. Drug Metab Dispos 35:2186-2195. (Pubitemid 350146204)
5. Hoffmann M, DeMaio W, Jordan RA, Talaat R, Harper D, Speth J, Scatina J. (2007). Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects. Drug Metab Dispos 35:1543-1553. (Pubitemid 47296047)
6. Hop CE, Wang Y, Kumar S, Elipe MV, Raab CE, Dean DC, Poon GK, Keohane CA, Strauss J, Chiu SH, Curtis N, Elliott J, Gerhard U, Locker K, Morrison D, Mortishire-Smith R, Thomas S, Watt AP, Evans DC. (2002). Identification of metabolites of a substance P (neurokinin 1 receptor) antagonist in rat hepatocytes and rat plasma. Drug Metab Dispos 30:937-943. (Pubitemid 34815425)
7. ICH, International Committee on Harmonization, Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals, M3(R2), 11 June 2009. Available at: http://www.ich.org/products/guidelines/multidisciplinary/article/ multidisciplinary-guidelines.html. Accessed on 1 May 2012.
8. Mutlib AE, Gerson RJ, Meunier PC, Haley PJ, Chen H, Gan LS, Davies MH, Gemzik B, Christ DD, Krahn DF, Markwalder JA, Seitz SP, Robertson RT, Miwa GT. (2000). The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats. Toxicol Appl Pharmacol 169:102-113.
9. Obach RS, Nedderman AN, Smith DA. (2012). Radiolabelled massbalance excretion and metabolism studies in laboratory animals: are they still necessary? Xenobiotica 42:46-56.
10. Pass GJ, Carrie D, Boylan M, Lorimore S, Wright E, Houston B, Henderson CJ, Wolf CR. (2005). Role of hepatic cytochrome p450s in the pharmacokinetics and toxicity of cyclophosphamide: studies with the hepatic cytochrome p450 reductase null mouse. Cancer Res 65:4211-4217. (Pubitemid 40775659)
11. Penner N, Xu L, Prakash C. (2012). Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how? Chem Res Toxicol 25:513-531.
12. Pollak PT, Bouillon T, Shafer SL. (2000). Population pharmacokinetics of long-term oral amiodarone therapy. Clin Pharmacol Ther 67:642-652. (Pubitemid 30416080)
13. Prakash C, Kamel A, Gummerus J, Wilner K. (1997). Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans. Drug Metab Dispos 25:863-872. (Pubitemid 27318605)
14. Prakash C, Johnson KA, Gardner MJ. (2008a). Disposition of lasofoxifene, a next-generation selective estrogen receptor modulator, in healthy male subjects. Drug Metab Dispos 36:1218-1226. (Pubitemid 351929303)
15. Prakash C, Johnson KA, Schroeder CM, Potchoiba MJ. (2008b). Metabolism, distribution, and excretion of a next generation selective estrogen receptor modulator, lasofoxifene, in rats and monkeys. Drug Metab Dispos 36:1753-1769.
16. Prakash C, Chen W, Rossulek M, Johnson K, Zhang C, O'Connell T, Potchoiba M, Dalvie D. (2008c). Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: characterization of unusual and novel metabolites by high-resolution liquid chromatographytandem mass spectrometry and 1H nuclear magnetic resonance. Drug Metab Dispos 36:2064-2079.
17. Smith DA, Dalvie D. (2012). Why do metabolites circulate? Xenobiotica 42:107-126.
18. U.S. FDA, United States Food and Drug Administration Guidance for Industry, Safety testing of drug metabolites, February 2008. Available at: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ ucm065014.htm. Accessed on 1 May 2012.
19. U.S. FDA, United States Food and Drug Administration Guidance for Industry, Drug interaction studies-study design, data analysis, implications for dosing, and labeling recommendations, February 2012. Available at: www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM292362.pdf. Accessed on 1 May 2012.
20. Zhang D, Raghavan N, Chando T, Gambardella J, Fu Y, Zhang D, Unger SE, Humphreys WG. (2007). LC-MS/MS-based approach for obtaining exposure estimates of metabolites in early clinical trials using radioactive metabolites as reference standards. Drug Metab Lett 1:293-298.
21. Zhu M, Zhang H, Humphreys WG. (2011). Drug metabolite profiling and identification by high-resolution mass spectrometry. J Biol Chem 286:25419-25425.